Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
The aim of the Marie Sklodowska-Curie Doctoral Network “eRaDicate” is to develop new therapies against cancer stem cell-driven relapse and metastasis. Our 11 doctoral candidates (DCs) of eRaDicate will be trained not only to perform original and independent research on an internationally competitive level, but will also be endowed with a creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
Recruitment of our fellows has been completed. They will start their contracts in the fall of 2024. Watch this space for updates and an introduction to our fellows.
News
Geoffrey Brown Recognized as Highly Ranked Scholar by ScholarGPS
eRaDicate consortium member Geoffrey Brown from University of Birmingham has been named a Highly Ranked Scholar™ by…
Very successful participation in the PUMA Grand Challenge by Carmen Colin
We are thrilled to congratulate Carmen Colin Tenorio on her remarkable achievement in the PUMA Grand Challenge. Hosted by the Department of Medical Oncology at the…
Carmen Colin’s first secondment to the Medical University of Vienna
From November 10th to 21st, 2025, I had the incredible opportunity to spend two weeks on a secondment at the Department of Pathology at the Medical University of Vienna. Under the guidance of…
Consortium
The eRaDicate consortium consists of eight academic and one industrial and beneficiaries, as well as twelve associated partners to provide training and secondments.
Beneficiaries
Associated Partners
